These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 26494789)
1. Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells. Dai H; Ding H; Meng XW; Peterson KL; Schneider PA; Karp JE; Kaufmann SH Genes Dev; 2015 Oct; 29(20):2140-52. PubMed ID: 26494789 [TBL] [Abstract][Full Text] [Related]
2. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53. Zhang J; Huang K; O'Neill KL; Pang X; Luo X Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874 [TBL] [Abstract][Full Text] [Related]
3. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells. Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126 [TBL] [Abstract][Full Text] [Related]
4. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. Gomez-Bougie P; Maiga S; Tessoulin B; Bourcier J; Bonnet A; Rodriguez MS; Le Gouill S; Touzeau C; Moreau P; Pellat-Deceunynck C; Amiot M Blood; 2018 Dec; 132(25):2656-2669. PubMed ID: 30309889 [TBL] [Abstract][Full Text] [Related]
5. Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis. Gomez-Bougie P; Halliez M; Moreau P; Pellat-Deceunynck C; Amiot M Cancer Lett; 2016 Dec; 383(2):204-211. PubMed ID: 27697610 [TBL] [Abstract][Full Text] [Related]
6. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235 [TBL] [Abstract][Full Text] [Related]
7. Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane. O'Neill KL; Huang K; Zhang J; Chen Y; Luo X Genes Dev; 2016 Apr; 30(8):973-88. PubMed ID: 27056669 [TBL] [Abstract][Full Text] [Related]
9. In non-transformed cells Bak activates upon loss of anti-apoptotic Bcl-XL and Mcl-1 but in the absence of active BH3-only proteins. Senft D; Weber A; Saathoff F; Berking C; Heppt MV; Kammerbauer C; Rothenfusser S; Kellner S; Kurgyis Z; Besch R; Häcker G Cell Death Dis; 2015 Nov; 6(11):e1996. PubMed ID: 26610208 [TBL] [Abstract][Full Text] [Related]
10. Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer. Liu D; Hou X; Wu W; Zanfagnin V; Li Y; Correia C; Zhao Z; Zhao C; Liu Z; Zhang T; Fang Z; Wang H; Xu C; Weroha SJ; Kaufmann SH; Dai H Cell Death Dis; 2021 Aug; 12(8):789. PubMed ID: 34385422 [TBL] [Abstract][Full Text] [Related]
11. Caspase-mediated Bak activation and cytochrome c release during intrinsic apoptotic cell death in Jurkat cells. Shawgo ME; Shelton SN; Robertson JD J Biol Chem; 2008 Dec; 283(51):35532-8. PubMed ID: 18927073 [TBL] [Abstract][Full Text] [Related]
12. Regulation of stress-induced nuclear protein redistribution: a new function of Bax and Bak uncoupled from Bcl-x(L). Lindenboim L; Blacher E; Borner C; Stein R Cell Death Differ; 2010 Feb; 17(2):346-59. PubMed ID: 19816507 [TBL] [Abstract][Full Text] [Related]
13. Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer. Nakajima W; Sharma K; Hicks MA; Le N; Brown R; Krystal GW; Harada H Cancer Biol Ther; 2016; 17(1):27-35. PubMed ID: 26575826 [TBL] [Abstract][Full Text] [Related]
15. Pan-BH3 mimetic S1 exhibits broad-spectrum antitumour effects by cooperation between Bax and Bak. Song T; Xue Z; Zhang Z; Shen X; Li X Basic Clin Pharmacol Toxicol; 2013 Sep; 113(3):145-51. PubMed ID: 23557083 [TBL] [Abstract][Full Text] [Related]
16. NBK/BIK antagonizes MCL-1 and BCL-XL and activates BAK-mediated apoptosis in response to protein synthesis inhibition. Shimazu T; Degenhardt K; Nur-E-Kamal A; Zhang J; Yoshida T; Zhang Y; Mathew R; White E; Inouye M Genes Dev; 2007 Apr; 21(8):929-41. PubMed ID: 17403773 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the BH3-only protein Puma as a direct Bak activator. Dai H; Pang YP; Ramirez-Alvarado M; Kaufmann SH J Biol Chem; 2014 Jan; 289(1):89-99. PubMed ID: 24265320 [TBL] [Abstract][Full Text] [Related]
18. Conversion of Bim-BH3 from Activator to Inhibitor of Bak through Structure-Based Design. Brouwer JM; Lan P; Cowan AD; Bernardini JP; Birkinshaw RW; van Delft MF; Sleebs BE; Robin AY; Wardak A; Tan IK; Reljic B; Lee EF; Fairlie WD; Call MJ; Smith BJ; Dewson G; Lessene G; Colman PM; Czabotar PE Mol Cell; 2017 Nov; 68(4):659-672.e9. PubMed ID: 29149594 [TBL] [Abstract][Full Text] [Related]
19. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Olejniczak SH; Hernandez-Ilizaliturri FJ; Clements JL; Czuczman MS Clin Cancer Res; 2008 Mar; 14(5):1550-60. PubMed ID: 18316580 [TBL] [Abstract][Full Text] [Related]
20. Anti-apoptotic Bcl-2 fails to form efficient complexes with pro-apoptotic Bak to protect from Celecoxib-induced apoptosis. Rudner J; Elsaesser SJ; Jendrossek V; Huber SM Biochem Pharmacol; 2011 Jan; 81(1):32-42. PubMed ID: 20836993 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]